AI Analysis | Feedback

It's like **Amazon Web Services (AWS)**, but for pharmaceutical research and development.

It's like **Quest Diagnostics** or **Labcorp**, but for developing new drugs instead of testing patients.

Think of it as the **Foxconn** for drug development, handling the specialized research and testing that pharmaceutical companies outsource.

AI Analysis | Feedback

• Research Models: Production and sale of various rodent research model strains, purpose-bred rats, and mice for research.
• Genetically Engineered Models and Services: Development and support services for genetically engineered research models.
• Research Animal Support Services: Includes insourcing solutions and diagnostic services to assist clients in using research models.
• Early Drug Discovery Services: Identification and validation of novel targets, chemical compounds, and antibodies.
• Non-Clinical Safety Assessment Services: Comprehensive toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics testing.
• In Vitro Quality Control Testing: Conventional and rapid quality control testing for sterile and non-sterile pharmaceuticals and consumer products.
• Specialized Biologics Testing: Outsourced specialized testing services for biologics.
• Avian Vaccine Services: Provision of specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products for vaccine manufacturing.
• Contract Vivarium Operation Services: Management and operation services for biopharmaceutical clients' vivariums.

AI Analysis | Feedback

AI Analysis | Feedback

null

AI Analysis | Feedback

James C. Foster, Chair, President & Chief Executive Officer

James C. Foster has had a distinguished 50-year career at Charles River Laboratories, joining in 1976 as Vice President of Administration and General Counsel. He was named President in 1991, Chief Executive Officer in 1992, and Chairman in 2000. Foster led a leveraged buyout of Charles River from Bausch & Lomb in 1999 and subsequently took the company public in an initial public offering in 2000. Under his leadership, Charles River expanded from a niche research models business to a global preclinical contract research organization, completing over 50 acquisitions. He was named Forbes magazine's Entrepreneur of the Year in 2003. Foster plans to retire as CEO in May 2026.

Birgit Girshick, Corporate Executive Vice President & Chief Operating Officer (Incoming Chief Executive Officer)

Birgit Girshick joined Charles River in 1989 and has held various positions of increasing responsibility across several business units, including Research Models and Services (RMS) Germany, Avian Vaccine Services, Biologics Testing Solutions, and Global Discovery Services. She was promoted to Corporate Executive Vice President in 2018, overseeing Discovery, Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services. In 2021, she also took responsibility for the Cell and Gene Therapy CDMO business. Girshick became Chief Operating Officer in October 2021, adding oversight of the Research Models and Services business. She is slated to succeed James C. Foster as Chief Executive Officer in May 2026.

Michael G. Knell, Corporate Senior Vice President, Interim Chief Financial Officer and Chief Accounting Officer

Michael G. Knell joined Charles River in April 2017 as Corporate Senior Vice President and Chief Accounting Officer. In September 2025, he also assumed the role of interim Chief Financial Officer. In these roles, he is responsible for strategic guidance to finance groups, including Global Accounting, Financial Planning and Analysis, Treasury, and Tax functions, and maintaining fiscal records and financial reports. Prior to Charles River, Mr. Knell served as Chief Accounting Officer and Vice President of Finance at Bruker Corporation from 2012 to 2017. He also spent 13 years at Ernst & Young LLP, where he was a Partner in Assurance Services.

Glenn G. Coleman, Incoming Chief Financial Officer

Glenn G. Coleman is set to join Charles River as Corporate Executive Vice President and Chief Financial Officer on April 6, 2026. He brings over 30 years of financial and operational management experience, with more than a decade in senior leadership roles within the healthcare sector. Most recently, since 2024, Coleman served as Chief Financial Officer and Chief Administrative Officer of a $1-billion healthcare services business. Prior to that, he was the CFO of two public companies, DENTSPLY SIRONA Inc. (from 2022 to 2024) and Integra Life Sciences Holdings Corporation. At Integra, he also held operational leadership positions, including Executive Vice President and Chief Operating Officer.

Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer

Matthew L. Daniel joined Charles River in 2005 as Senior Corporate Counsel, focusing on mergers & acquisitions and securities. He advanced through several roles, becoming Deputy General Counsel in 2010, and Corporate Vice President, Legal Compliance & Deputy General Counsel in 2011. In 2017, he was named a Corporate Senior Vice President, and in 2020, he assumed his current position as General Counsel, Corporate Secretary, and Chief Compliance Officer. His responsibilities include leading the global Legal function, overseeing corporate secretary functions, securities, M&A, employment and litigation, legal compliance, intellectual property, corporate governance, and the global Security function. Prior to Charles River, Daniel was a corporate attorney at Goodwin Procter LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP.

AI Analysis | Feedback

Key Risks to Charles River Laboratories International (CRL)

The key risks to Charles River Laboratories International include the evolving regulatory landscape and the emergence of alternative testing methods, the cyclicality and volatility in pharmaceutical and biotechnology R&D spending, and intense competition within the contract research organization (CRO) market.

The most significant risk stems from the

evolving regulatory landscape and the emergence of alternative testing methods. Charles River Laboratories heavily relies on providing research models and conducting in vivo safety assessments, particularly within its Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) segments. Increasing animal welfare regulations, coupled with the advancement and adoption of in vitro, organ-on-a-chip, and in silico (computer modeling) methods, could significantly reduce the demand for traditional animal testing, directly impacting a core part of CRL's business model.

A second key risk is the

cyclicality and volatility in pharmaceutical and biotechnology R&D spending. As a contract research organization, CRL's revenues are directly tied to the research and development budgets and pipelines of its biopharmaceutical clients. Economic downturns, changes in client priorities, reduced venture capital funding for smaller biotech firms, or a general slowdown in drug approvals could lead to decreased outsourcing demand for CRL's discovery, development, and safety testing services.

Finally,

intense competition within the contract research organization (CRO) market poses a continuous risk. CRL operates in a competitive environment with numerous other CROs offering similar services. Furthermore, large pharmaceutical and biotechnology companies may choose to insource more of their research and development activities, potentially reducing their reliance on external service providers like Charles River Laboratories and exerting pricing pressure on existing contracts.

AI Analysis | Feedback

The accelerating development and regulatory acceptance of non-animal alternative testing methods, such as organ-on-a-chip technology, advanced in vitro models, and computational toxicology/AI for drug discovery, non-clinical development, and safety assessment. This trend could reduce the demand for traditional animal models and associated in vivo services, impacting Charles River Laboratories' Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) segments.

AI Analysis | Feedback

Research Models and Services (RMS)

Discovery and Safety Assessment (DSA)

Manufacturing Solutions

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Charles River Laboratories International (CRL) over the next 2-3 years:

1. Rebound in Discovery and Safety Assessment (DSA) Services: Charles River Laboratories anticipates a return to organic revenue growth in the second half of 2026, primarily driven by robust booking trends in its Discovery and Safety Assessment (DSA) segment that were observed in late 2025. This indicates an improved demand environment for drug development services from biopharmaceutical clients.
2. Organic Growth in Manufacturing Solutions: The company expects an increase in organic revenue within its Manufacturing segment. This growth is supported by a solid performance from the Microbial Solutions business and strategic restructuring initiatives.
3. Strategic Acquisitions: Charles River Laboratories is focusing on strategic acquisitions that align with its core strengths, aiming to boost efficiency and strengthen its position in the biopharmaceutical sector. For instance, the acquisition of K.F. Cambodia is projected to enhance the non-human primate (NHP) supply chain, reduce sourcing costs in the DSA segment, and contribute to operating margin improvements, which can indirectly support revenue growth by enabling more studies and improving service delivery.
4. Stabilizing Biopharmaceutical Demand Environment: The overall biopharma demand environment is showing signs of stabilization, with a reported decline in study cancellations and increased demand for drug development services. This broader market recovery provides a foundational driver for Charles River's revenue growth across its service offerings.

AI Analysis | Feedback

1. Share Repurchases

• Charles River Laboratories' Board of Directors approved a new $1.0 billion stock repurchase authorization in October 2025, which replaced the previous authorization.
• Under the prior authorization, the company repurchased $450.7 million in common stock since August 2024.
• The annual share buybacks amounted to $360.673 million in 2025, $119.175 million in 2024, and $24.155 million in 2023.

4. Outbound Investments

• In 2021, Charles River Laboratories acquired Cognate BioServices for $875 million, marking a strategic re-entry into the cell and gene therapy Contract Development and Manufacturing Organization (CDMO) sector and including investments in three Centers of Excellence.
• The company has invested $300 million in alternative technologies, with a particular focus on New Approach Methodologies (NAMs).
• Charles River Laboratories is evaluating opportunities to enhance its scientific capabilities in bioanalysis and in vitro services, and to strengthen its geographic presence through strategic acquisitions, technology partnerships, and internal development efforts.

5. Capital Expenditures

• Capital expenditures were -$219.2 million in 2025 and -$233.0 million in 2024.
• Capital expenditures reached a five-year peak in December 2022 at $324.7 million.
• The company is making significant investments in state-of-the-art equipment and infrastructure to support a growing client base and meet increasing demand for preclinical services, including expanding laboratory facilities.